The role of bisphosphonates in the treatment of prostate cancer

BJU International

Volumn 95, Issue 7, 2005, Pages 935-938

  Parker, Christopher C ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; MITOXANTRONE; PAMIDRONIC ACID; PREDNISOLONE; ZOLEDRONIC ACID;

ANEMIA; BONE DISEASE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; FATIGUE; FEVER; FRACTURE; HEMANGIOPERICYTOMA; HUMAN; KIDNEY ISCHEMIA; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SHORT SURVEY; SIDE EFFECT; SPINAL CORD COMPRESSION; TUMOR CLASSIFICATION; WEIGHT REDUCTION;

ANDROGEN ANTAGONISTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III; CLODRONIC ACID; DIPHOSPHONATES; FORECASTING; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 18544374984     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05441.x     Document Type: Short Survey

References (9)

1. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469
2. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PRO5 Trial). J Natl Cancer Inst 2003; 95: 1300-11
3. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-42
4. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
5. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-84
6. Mason MC and MRC PRO4 Collaborators; University of Wales College of Medicine, UK. Development of bone metastases from prostate cancer: first results of the MRC PRO4 randomised controlled trial (ISCRTN61384873). ASCO, 40th Annual Meeting, June 5-8, 2004, New Orleans, Louisiana. J Clin Oncol 2004; 22: 384, A4511
7. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82
8. Eisenberger M et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). ASCO, 40th Annual Meeting, June 5-8, 2004, J Clin Oncol 2004; 22: 2, A4
9. Magnetto S et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263-9